Last reviewed · How we verify

BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg — Competitive Intelligence Brief

BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg (bnt162b2-monovalent-omi-xbb-1-5-30-mcg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 1 RNA therapeutics Live · refreshed every 30 min

Target snapshot

BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg (bnt162b2-monovalent-omi-xbb-1-5-30-mcg) — Pfizer Inc..

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg TARGET bnt162b2-monovalent-omi-xbb-1-5-30-mcg Pfizer Inc. phase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b2-monovalent-omi-xbb-1-5-30-mcg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: